Trial Profile
A Retrospective Study Assessing The Effect of Ra-223 Treatment on Patterns of Progression in Bone and Soft Tissue in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2018
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 14 Mar 2018 New trial record
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium.